People with partial resistance to Alzheimer’s could inspire new drugs
16 May 2023
Dr Stephanie Fowler (UCL Queen Square Institute of Neurology) highlighted that treatments called antisense oligonucleotides are in development that reduce cells’ manufacturing of tau which play a key role in Alzheimer’s disease pathophysiology.